 MARINA DEL REY, Calif., March 17, 2021 PRNewswire -- Armata Pharmaceuticals, Inc. NYSE American: ARMP Armata or the Company, a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Companys 20 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. NASDAQ: INVA together, Innoviva. 